Literature DB >> 30679280

Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells.

Christine E Nelson1,2, Lauren J Mills3, Jennifer L McCurtain1, Emily A Thompson1,2, Davis M Seelig4, Siddheshvar Bhela1,2, Clare F Quarnstrom1,2, Brian T Fife2,5, Vaiva Vezys6,2.   

Abstract

Established T cell dysfunction is a barrier to antitumor responses, and checkpoint blockade presumably reverses this. Many patients fail to respond to treatment and/or develop autoimmune adverse events. The underlying reason for T cell responsiveness remains elusive. Here, we show that susceptibility to checkpoint blockade is dependent on the activation status of T cells. Newly activated self-specific CD8 T cells respond to checkpoint blockade and cause autoimmunity, which is mitigated by inhibiting the mechanistic target of rapamycin. However, once tolerance is established, self-specific CD8 T cells display a gene signature comparable to tumor-specific CD8 T cells in a fixed state of dysfunction. Tolerant self-specific CD8 T cells do not respond to single or combinatorial dosing of anti-CTLA4, anti-PD-L1, anti-PD-1, anti-LAG-3, and/or anti-TIM-3. Despite this, T cell responsiveness can be induced by vaccination with cognate antigen, which alters the previously fixed transcriptional signature and increases antigen-sensing machinery. Antigenic reeducation of tolerant T cells synergizes with checkpoint blockade to generate functional CD8 T cells, which eliminate tumors without concomitant autoimmunity and are transcriptionally distinct from classic effector T cells. These data demonstrate that responses to checkpoint blockade are dependent on the activation state of a T cell and show that checkpoint blockade-insensitive CD8 T cells can be induced to respond to checkpoint blockade with robust antigenic stimulation to participate in tumor control.

Entities:  

Keywords:  CD8 T cells; checkpoint; dysfunction; tolerance; tumor

Mesh:

Substances:

Year:  2019        PMID: 30679280      PMCID: PMC6377494          DOI: 10.1073/pnas.1810326116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice.

Authors:  Kristen E Pauken; Jonathan L Linehan; Justin A Spanier; Nathanael L Sahli; Lokesh A Kalekar; Bryce A Binstadt; James J Moon; Daniel L Mueller; Marc K Jenkins; Brian T Fife
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

Review 2.  Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

Authors:  Jessica C Hassel; Lucie Heinzerling; Jens Aberle; Oliver Bähr; Thomas K Eigentler; Marc-Oliver Grimm; Victor Grünwald; Jan Leipe; Niels Reinmuth; Julia K Tietze; Jörg Trojan; Lisa Zimmer; Ralf Gutzmer
Journal:  Cancer Treat Rev       Date:  2017-05-18       Impact factor: 12.111

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

4.  Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.

Authors:  Andrea Schietinger; Jeffrey J Delrow; Ryan S Basom; Joseph N Blattman; Philip D Greenberg
Journal:  Science       Date:  2012-01-19       Impact factor: 47.728

Review 5.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

Authors:  H Nishimura; M Nose; H Hiai; N Minato; T Honjo
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

Review 8.  Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Authors:  Brian T Fife; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

9.  Cutting edge: generation of effector cells that localize to mucosal tissues and form resident memory CD8 T cells is controlled by mTOR.

Authors:  Ryan T Sowell; Magdalena Rogozinska; Christine E Nelson; Vaiva Vezys; Amanda L Marzo
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

Review 10.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

View more
  8 in total

1.  Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.

Authors:  Fatma Babikr; Jiangbo Wan; Aizhang Xu; Zhaojia Wu; Shahid Ahmed; Andrew Freywald; Rajni Chibbar; Yue Wu; Michael Moser; Gary Groot; Wenjun Zhang; Bing Zhang; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2021-11-15       Impact factor: 11.530

2.  Assessment of the prognostic value of SPOCK1 in clear cell renal cell carcinoma: a bioinformatics analysis.

Authors:  Jie Chen; Ziqi Ye; Lulu Liu; Bixia Xuan
Journal:  Transl Androl Urol       Date:  2022-04

3.  Ectopic expression of LAG-3 in non-small-cell lung cancer cells and its clinical significance.

Authors:  Chenglong Ma; Xiao Sun; Dong Shen; Yuejun Sun; Naifu Guan; Chunjian Qi
Journal:  J Clin Lab Anal       Date:  2020-02-20       Impact factor: 2.352

4.  Robust Iterative Stimulation with Self-Antigens Overcomes CD8+ T Cell Tolerance to Self- and Tumor Antigens.

Authors:  Christine E Nelson; Emily A Thompson; Clare F Quarnstrom; Kathryn A Fraser; Davis M Seelig; Siddheshvar Bhela; Brandon J Burbach; David Masopust; Vaiva Vezys
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

Review 5.  Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.

Authors:  Simone Nüssing; Joseph A Trapani; Ian A Parish
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

6.  Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma.

Authors:  Siyuan Dai; Han Zeng; Zhaopei Liu; Kaifeng Jin; Wenbin Jiang; Zewei Wang; Zhiyuan Lin; Ying Xiong; Jiajun Wang; Yuan Chang; Qi Bai; Yu Xia; Li Liu; Yu Zhu; Le Xu; Yang Qu; Jianming Guo; Jiejie Xu
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

7.  Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy.

Authors:  Nancy D Ebelt; Edith Zuniga; Monica Marzagalli; Vic Zamloot; Bruce R Blazar; Ravi Salgia; Edwin R Manuel
Journal:  Biomedicines       Date:  2020-12-16

8.  Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.

Authors:  Brandon J Burbach; Stephen D O'Flanagan; Qi Shao; Katharine M Young; Joseph R Slaughter; Meagan R Rollins; Tami Jo L Street; Victoria E Granger; Lalit K Beura; Samira M Azarin; Satish Ramadhyani; Bruce R Forsyth; John C Bischof; Yoji Shimizu
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.